Prothena
PRTA8.7000.57% ( -0.050 )
Prothena (PRTA)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by prote...
- Open
- 8.880
- High
- 9.130
- Low
- 8.660
- Prev. Close
- 8.750
- Volume
- 704.71K
- Turnover
- 6.19M
- Avg Price
- 8.777
- Bid/Ask Ratio
- --
- Amplitude
- 5.37%
- 52wk High
- 11.800
- Volume Ratio
- 1.19
- Turnover Ratio
- 1.92%
Prothena Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$21.40145.98%
Forecast & RatingHold
6analysts
- Strong buy16.67%
- Buy33.33%
- Hold33.33%
- Sell0.00%
- Strong sell16.67%
News
- Simplywall · 18 hours ago
Top Growth Companies With Insider Ownership For July 2026
- Market Beat · 19 hours ago
Prothena (PRTA) Expected to Announce Quarterly Earnings on Monday
- Tip Ranks · Jul 24 at 07:25 AM
Analyst Reiterates Buy on Prothena, Maintains $30 Price Target on Differentiated TTR-Depleter Opportunity
- Global Report · Jul 4 at 04:01 AM
The Biotech Survival Curve: How Milestone Checks and In-Vivo CRISPR Are Rewriting the Rules
- PUBT · Jun 18 at 10:39 AM
Prothena 10% owner William P. Scully buys 20,000 shares worth $157,990
- Tip Ranks · Jun 15 at 06:26 AM
3 Stocks Flashing Positive Insider Buying Signals
